Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

  • Technology appraisal guidance
  • TA388
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

A. The evidence review group (ERG) report for this appraisal was prepared by BMJ Group:

  • Edwards SJ, Crawford F, Osei-Assibey G Bacelar M, Berardi A, Salih F. Sacubitril valsartan for treating chronic heart failure: A Single Technology Appraisal. BMJ-TAG, 2015.

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Novartis

II. Professional/expert and patient/carer groups:

  • British Cardiology Society

  • British Heart Foundation

  • Pumping Marvellous Foundation

  • South Asian Health Foundation

  • British Society for Heart Failure

  • Royal College of Pathologists

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • NHS Doncaster CCG

  • NHS England

  • NHS Surrey Heath CCG

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Servier

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on sacubitril valsartan for treating heart failure with reduced ejection fraction by attending the initial committee discussion and providing a written statement to the committee. They are invited to comment on the ACD.

  • Dr Simon Williams, Consultant Cardiologist, nominated by Novartis – clinical expert

  • Dr Lisa Anderson, Heart Failure Consultant, nominated by The British Society for Heart Failure – clinical expert

  • Nick Hartshorne-Evans, nominated by Pumping Marvellous Foundation – patient expert

  • Emma Taylor, nominated by Pumping Marvellous Foundation – patient expert

E. Representatives from the following company attended committee meetings. They contributed only when asked by the committee chair to clarify specific issues and comment on factual accuracy.

  • Novartis Pharmaceuticals

ISBN: 978-1-4731-1818-8